Arsenal Biosciences slashes workforce to focus on in vivo CAR-T strategy
Arsenal Biosciences is reducing its headcount again, letting go of most employees as it shifts its focus toward in vivo CAR-T therapies. This follows a previous layoff of half its staff about a year ago. The company's strategic pivot aims to advance its cell therapy pipeline with a new approach.
Arsenal Biosciences is making a second, deeper round of cuts, reducing its workforce to a fraction of its former size. The company is redirecting its resources toward in vivo CAR-T therapies, a field that aims to engineer patients’ own cells directly inside the body, rather than manufacturing them in a lab. This pivot follows a layoff of roughly half its staff about a year ago, signaling a rapid strategic consolidation. The remaining team will focus on advancing a cell therapy pipeline built around this newer delivery approach, though specific program details were not disclosed.
This shift could signal a broader industry recalibration, as smaller biotechs face pressure to prioritize high-risk, high-reward platforms over broader pipelines. Patients may eventually benefit from more accessible CAR-T treatments if in vivo methods prove viable, but near-term, employees and local research ecosystems bear the immediate impact. Investors and partners will watch closely, as repeated layoffs may affect confidence in the company’s execution.